Equity Grants

4D Molecular Therapeutics has granted 23,600 RSUs to four new employees under its 2025 Employment Inducement Award Plan. This move reflects the company’s strategy to attract and retain key talent in the competitive biotech sector. These inducement grants, common in the industry, are intended to incentivize new hires and support the advancement of the company’s gene therapy pipeline, including its lead candidate 4D-150.

BrandPilot AI settled a $17,272.75 liability by issuing 690,910 Debt Settlement Units—each containing a common share and a warrant exercisable at $0.05 for up to 24 months—at a deemed $0.025 per unit, with a 4‑month‑plus‑1‑day hold. Simultaneously, it granted 2.8 million stock options (exercise $0.05, three‑year vest, exercisable through Dec 1 2030) and 5.05 million RSUs (vesting Dec 1 2028). All awards were made under the omnibus equity incentive plan approved on May 31 2024, aiming to preserve cash and align executive compensation with growth.